BACKGROUND: Smoking remains the primary preventable cause of death and illness in the U.S. Effective, convenient treatment programs are needed to reduce smoking prevalence. PURPOSE: This study compared the effectiveness of three modalities of a behavioral smoking-cessation program in smokers usingvarenicline. METHODS:Current treatment-seeking smokers (n=1202) were recruited from a large healthcare organization between October 2006 and October 2007. Eligible participants were randomized to one of three smoking-cessation interventions: web-based counseling (n=401); proactive telephone-based counseling (PTC; n=402); or combined PTC and web counseling (n=399). All participants received a standard 12-week FDA-approved course of varenicline. Self-report determined the primary outcomes (7-day point prevalent abstinence at 3- and 6-month follow-ups); the number of days varenicline was taken; and treatment-related symptoms. Behavioral measures determined utilization of both the web- and Phone-based counseling. RESULTS: Intent-to-treat analyses revealed relatively high percentages of abstinence at 3 months (38.9%, 48.5%, 43.4%) and at 6 months (30.7%, 34.3%, 33.8%) for the web, PTC, and PTC-web groups, respectively. The PTC group had a significantly higher percentage of abstinence than the web group at 3 months (OR=1.48, 95% CI=1.12, 1.96), but no between-group differences in abstinence outcomes were seen at 6 months. CONCLUSIONS:Phone counseling had greater treatment advantage for early cessation and appeared to increase medication adherence, but the absence of differences at 6 months suggests that any of the interventions hold promise when used in conjunction with varenicline. 2010 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND: Smoking remains the primary preventable cause of death and illness in the U.S. Effective, convenient treatment programs are needed to reduce smoking prevalence. PURPOSE: This study compared the effectiveness of three modalities of a behavioral smoking-cessation program in smokers using varenicline. METHODS: Current treatment-seeking smokers (n=1202) were recruited from a large healthcare organization between October 2006 and October 2007. Eligible participants were randomized to one of three smoking-cessation interventions: web-based counseling (n=401); proactive telephone-based counseling (PTC; n=402); or combined PTC and web counseling (n=399). All participants received a standard 12-week FDA-approved course of varenicline. Self-report determined the primary outcomes (7-day point prevalent abstinence at 3- and 6-month follow-ups); the number of days varenicline was taken; and treatment-related symptoms. Behavioral measures determined utilization of both the web- and Phone-based counseling. RESULTS: Intent-to-treat analyses revealed relatively high percentages of abstinence at 3 months (38.9%, 48.5%, 43.4%) and at 6 months (30.7%, 34.3%, 33.8%) for the web, PTC, and PTC-web groups, respectively. The PTC group had a significantly higher percentage of abstinence than the web group at 3 months (OR=1.48, 95% CI=1.12, 1.96), but no between-group differences in abstinence outcomes were seen at 6 months. CONCLUSIONS: Phone counseling had greater treatment advantage for early cessation and appeared to increase medication adherence, but the absence of differences at 6 months suggests that any of the interventions hold promise when used in conjunction with varenicline. 2010 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
Authors: Ay El-Bastawissi; T McAfee; S M Zbikowski; J Hollis; M Stark; K Wassum; N Clark; R Barwinski; E Broughton Journal: Tob Control Date: 2003-03 Impact factor: 7.552
Authors: C T Orleans; V J Schoenbach; E H Wagner; D Quade; M A Salmon; D C Pearson; J Fiedler; C Q Porter; B H Kaplan Journal: J Consult Clin Psychol Date: 1991-06
Authors: Maya K Leabman; Conrad C Huang; Doug Stryke; Susan J Johns; Michiko Kawamoto; Thomas E Ferrin; Joseph DeYoung; Travis R Taylor; Melanie De La Cruz; Ira Herskowitz; Kathleen M Giacomini Journal: Pharmacol Rev Date: 2003-07-17 Impact factor: 25.468
Authors: Jennifer B McClure; Gary E Swan; Lisa Jack; Sheryl L Catz; Susan M Zbikowski; Tim A McAfee; Mona Deprey; Julie Richards; Harold Javitz Journal: J Gen Intern Med Date: 2009-02-24 Impact factor: 5.128
Authors: Darla E Kendzor; Lorraine R Reitzel; Carlos A Mazas; Ludmila M Cofta-Woerpel; Yumei Cao; Lingyun Ji; Tracy J Costello; Jennifer Irvin Vidrine; Michael S Businelle; Yisheng Li; Yessenia Castro; Jasjit S Ahluwalia; Paul M Cinciripini; David W Wetter Journal: Soc Sci Med Date: 2012-02-23 Impact factor: 4.634
Authors: Susan M Zbikowski; Lisa M Jack; Jennifer B McClure; Mona Deprey; Harold S Javitz; Timothy A McAfee; Sheryl L Catz; Julie Richards; Terry Bush; Gary E Swan Journal: Nicotine Tob Res Date: 2011-01-31 Impact factor: 4.244
Authors: Harold S Javitz; Susan M Zbikowski; Mona Deprey; Timothy A McAfee; Jennifer B McClure; Julie Richards; Sheryl L Catz; Lisa M Jack; Gary E Swan Journal: Transl Behav Med Date: 2011-03-01 Impact factor: 3.046
Authors: Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Martha Michel; Denise Nishita; David V Conti; Christopher K Edlund; Pui-Yan Kwok; Jennifer B McClure; Richard B Kim; Sharon M Hall; Rachel F Tyndale; Timothy B Baker; Neal L Benowitz; Gary E Swan Journal: Nicotine Tob Res Date: 2014-08-20 Impact factor: 4.244
Authors: Jennifer B McClure; Gary E Swan; Sheryl L Catz; Lisa Jack; Harold Javitz; Tim McAfee; Mona Deprey; Julie Richards; Susan M Zbikowski Journal: J Subst Abuse Treat Date: 2010-04-02
Authors: Brian G Danaher; Herbert H Severson; Shu-Hong Zhu; Judy A Andrews; Sharon E Cummins; Edward Lichtenstein; Gary J Tedeschi; Coleen Hudkins; Chris Widdop; Ryann Crowley; John R Seeley Journal: Internet Interv Date: 2015-05-01
Authors: Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan Journal: Pharmacogenet Genomics Date: 2013-02 Impact factor: 2.089